Risankizumab,Ixekizumab,Secukinumab
abbvie,eli lilly,novartis,Boehringer Ingelheim
['psoriasis']
new data presented during a late-breaking research session at #aad2023 supports a switching strategy when #psoriasis medications result in a suboptimal response. 
Dermatology Times: The latest news and trends in dermatologic procedures, therapy, technology, products and drugs.